Navigation Links
Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
Date:10/20/2008

Ted Daley, President of Raptor's clinical division stated, "We are pleased that dosing is now underway in the Phase 2a clinical trial in NASH, a disease that may have a severe impact on the long-term health of a large number of people. Cysteamine represents an exciting potential treatment for NASH patients currently limited to diet and exercise for disease management. The NASH program is part of our strategy to leverage cysteamine's known safety profile and potential efficacy in several indications where it has already shown promise in clinical and preclinical studies."

Joel Lavine, M.D., Ph.D., pediatric gastroenterologist at UCSD and principal investigator for the NASH study, commented, "The initiation of patient dosing in the NASH trial offers the opportunity to evaluate a potential new treatment for this disorder. We're pleased to collaborate with Raptor for this study as we work to find a treatment for NASH."

NASH is believed to affect 2% to 5% of the U.S. population. While commonly diagnosed in insulin-resistant obese adults with diabetes and abnormal serum lipid profiles, NASH can also occur in children, elderly and non-diabetic persons of average weight. Though most people with NASH feel healthy and show no outward signs of liver disease, NASH causes decreased liver function and potentially leads to cirrhosis, liver failure and end-stage liver disease. In more severe cases, the progressive nature of NASH may require liver transplantation in affected patients.

About Cysteamine and DR Cysteamine

Cysteamine is cleared for market by the FDA and EMEA to treat cystinosis, a rare and genetic lysosomal storage disease. The drug's potential to accumulate in the liver may create a targeted treatment effect for patients with NASH. DR Cysteamine is designed as an enterically coated, oral formulation of cysteamine.

Raptor obtained an exclusive, worldwide license to DR Cysteamine, as well as orphan drug designation from the FDA for DR Cy
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
2. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
3. Raptor Pharmaceuticals Provides Update of Product Programs
4. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
5. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
6. Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement
7. Access Pharmaceuticals Presents New Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
8. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
9. Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
10. Critical Pharmaceuticals Enter Sustained Release hGH Arena
11. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... 4, 2015 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral drug ... in the upcoming Rodman & Renshaw 17 th ... in New York City .  Dr. ... a corporate overview on September 9, 2015. ...
(Date:9/4/2015)... 04, 2015 Research ... addition of the "Veterinary Pharmaceutical Submissions in ... conference to their offering. This ... of the constituent parts of the application for ... which a marketing authorisation is sought in the ...
(Date:9/4/2015)... September 4, 2015 Hutchison ... that Hutchison MediPharma Limited ("HMP"), its drug R&D ... second proof-of-concept ("POC") trial of fruquintinib in patients ... in China .  The top-line ... meeting the primary efficacy endpoint of progression free ...
Breaking Medicine Technology:Oramed to Present at the Rodman & Renshaw Global Investment Conference 2Oramed to Present at the Rodman & Renshaw Global Investment Conference 3Veterinary Pharmaceutical Submissions in the EU: Two day Course - London, UK - December 7-8, 2015 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 3
... Jan. 5, 2011 Although smoking is an expensive habit, ... quit smoking can seem like expensive purchases as well.  The ... try to do it "cold turkey" – the most popular ... to relapse.   The use of store brand ...
... Avaxia Biologics, Inc., a privately-held biotech company developing ... to the gastrointestinal tract, announced today that it ... of inflammatory bowel disease (IBD). Avaxia,s orally administered ... three different animal models and showed superior efficacy ...
Cached Medicine Technology:Resolved to Quit Smoking This Year? 2Resolved to Quit Smoking This Year? 3Avaxia Biologics, Inc. to Present Key Pre-Clinical Inflammatory Bowel Disease Remission Data at Biotech Showcase 2011 2
(Date:9/4/2015)... ... 2015 , ... After wearing the same uniforms for six seasons, the Sprayberry ... effort to assist the team, the Jones Agency, a locally owned insurance firm that ... for the new uniforms. , As is so often the case with high school ...
(Date:9/4/2015)... San Francisco, CA (PRWEB) , ... September 04, ... ... Ben Amini, announces that CEREC technology is now available at CitiDent. CEREC is ... milling machinery. In addition to saving time for patients by eliminating the need ...
(Date:9/4/2015)... ... September 04, 2015 , ... The USC Eye Institute is proud ... nationwide by Doximity. Faculty, residents and staff are honored to have contributed to ... quality of our ophthalmology residency program. Our faculty places a high priority on our ...
(Date:9/4/2015)... ... , ... Steven Winter Associates, Inc., (SWA) is pleased to ... the Residential Award of Merit by the Connecticut Green Building Council (CTGBC) for ... competitive field of submissions, the net-zero energy residence will be honored at the ...
(Date:9/4/2015)... ... September 04, 2015 , ... Friday night, Chicago lovebirds Jenny ... Rescue’s A Night of Hope event supporting families affected by autism, raising nearly $250,000. ... Joe Salas, joined together at the Oscar Swan Inn to support the cause. ...
Breaking Medicine News(10 mins):Health News:The Jones Agency Serves Up a Charity Drive to Fund New Uniforms for the Sprayberry High School Girls Volleyball Team 2Health News:The Jones Agency Serves Up a Charity Drive to Fund New Uniforms for the Sprayberry High School Girls Volleyball Team 3Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2Health News:USC Ophthalmology Residency Program Ranked in Top 10 by Doximity 2Health News:USC Ophthalmology Residency Program Ranked in Top 10 by Doximity 3Health News:South Glastonbury Home Selected for Award by Connecticut Green Building Council 2Health News:Jenny McCarthy & Donnie Wahlberg Help Raise Over $200,000 For Generation Rescue’s ‘Night Of Hope’ Chicago Charity Event 2
... the most important health consequences of climate change will be ... given much attention at the UN climate change conference in ... Howard from the Institute of Psychiatry (IoP) at King,s College ... the potential mental health impacts of climate change. ...
... to diabetes, cardiovascular trouble, , THURSDAY, Dec. 3 (HealthDay ... of months, can significantly lower a woman,s risk of ... risk factors -- years later, reports a new study ... . , In women who didn,t have pregnancy-related (gestational) ...
... ... ... 2, 2009 -- CS3 Technology, a leading professional services firm offering HRMS and ERP ... , ,Each year at their company-wide retreat, CS3 recognizes outstanding achievement among their employees. ...
... ... launch of its new ventral hernia repair system. Freedom Ventral is a modification to ... suturing. , ... December 3, 2009 -- Insightra Medical, Inc, a California based medical device company today ...
... , McALLEN, Texas, Dec. ... ), announced today that it has acquired three Texas ... Healthcare Center in McAllen, the 100-bed Alta Vista Rehabilitation ... & Healthcare in Harlingen. The acquisitions were effective December ...
... 3 The American Association of Poison Control Centers (AAPCC) ... an accredited poison control center - a major milestone for ... Hennepin Regional Poison Center among 58 accredited poison centers in ... means we have met the national standards of excellence for ...
Cached Medicine News:Health News:Major impacts of climate change expected on mental health 2Health News:Breast-Feeding Can Help Mom's Heart Decades Later 2Health News:Breast-Feeding Can Help Mom's Heart Decades Later 3Health News:CS3 Technology Announces Annual Employee Awards 2Health News:CS3 Technology Announces Annual Employee Awards 3Health News:Insightra Medical Launches the Freedom(TM) Ventral Hernia Repair, an Innovative New Way to Deploy Sublay Implants for Ventral Hernias Without Suturing 2Health News:Insightra Medical Launches the Freedom(TM) Ventral Hernia Repair, an Innovative New Way to Deploy Sublay Implants for Ventral Hernias Without Suturing 3Health News:Insightra Medical Launches the Freedom(TM) Ventral Hernia Repair, an Innovative New Way to Deploy Sublay Implants for Ventral Hernias Without Suturing 4Health News:The Ensign Group Acquires Three Texas Skilled Nursing Facilities 2Health News:The Ensign Group Acquires Three Texas Skilled Nursing Facilities 3Health News:Hennepin Regional Poison Center Designated as an Accredited Poison Control Center 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: